# MYPN

## Overview
The MYPN gene encodes the protein myopalladin, a sarcomeric protein predominantly expressed in striated muscle tissues, including cardiac and skeletal muscles. Myopalladin is characterized by its structural role within the sarcomere, particularly in the Z-line and I-band regions, where it contributes to muscle integrity and function. It is categorized as a structural protein due to its involvement in the assembly and maintenance of sarcomeric protein complexes. Myopalladin interacts with various proteins, such as α-actinin, nebulin, and nebulette, facilitating the stabilization of actin filaments and influencing muscle growth and differentiation through pathways like the serum response factor (SRF) pathway. Mutations in the MYPN gene are linked to several muscle-related diseases, including cardiomyopathies and nemaline myopathy, highlighting its clinical significance in muscle health and disease (Purevjav2012Molecular; Filomena2019Myopalladin; Bang2001Myopalladin).

## Structure
Myopalladin (MYPN) is a 145-kilodalton sarcomeric protein primarily expressed in striated muscle tissues, including cardiac and skeletal muscle. The protein is characterized by its five immunoglobulin (Ig) domains, which are part of the Ig-I subset, and are separated by six interdomain insertions (Bang2001Myopalladin). These domains contribute to its structural role in the sarcomere, particularly in the Z-line and I-band regions (Filomena2019Myopalladin).

The COOH-terminal region of myopalladin is involved in binding to α-actinin, while the NH2-terminal region binds to the cardiac ankyrin repeat protein (CARP) (Bang2001Myopalladin). Myopalladin also interacts with nebulin and nebulette through a proline-rich stretch in its central IS3 domain, which is crucial for binding to the SH3 domain of nebulin (Bang2001Myopalladin). This interaction is mediated by a proline residue triplet (PPP) at positions 649-651 (Bang2001Myopalladin).

Myopalladin's structure allows it to play a significant role in the assembly and maintenance of Z-disc and I-band protein complexes, contributing to sarcomeric integrity and muscle function (Bang2001Myopalladin). The protein's interactions and structural domains highlight its importance in muscle organization and function.

## Function
Myopalladin (MYPN) is a striated muscle-specific protein that plays a critical role in the structural organization and function of muscle cells. It is primarily localized in the Z-line and I-band of the sarcomere, where it interacts with various proteins to maintain muscle integrity and function (Filomena2019Myopalladin; Bang2001Myopalladin). MYPN binds to filamentous actin (F-actin), stabilizing it and preventing depolymerization, which is crucial for maintaining the structural integrity of muscle fibers (Filomena2019Myopalladin). This stabilization of actin filaments is essential for muscle contraction and the overall mechanical performance of muscle tissues (Caremani2014The).

MYPN also interacts with the serum response factor (SRF) pathway, influencing muscle growth and differentiation. It enhances the activity of myocardin-related transcription factors (MRTFs), which are coactivators of SRF, thereby promoting the expression of genes involved in muscle development and function (Filomena2019Myopalladin). The protein's role in modulating actin dynamics and SRF signaling is vital for muscle growth and maintenance, as evidenced by the reduced muscle fiber size and compromised muscle function observed in MYPN knockout models (Filomena2019Myopalladin).

## Clinical Significance
Mutations in the MYPN gene, which encodes the protein myopalladin, are associated with several cardiomyopathies, including dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), and restrictive cardiomyopathy (RCM). These mutations can lead to structural and functional abnormalities in cardiac cells, contributing to heart failure and arrhythmias (Filomena2021Myopalladin; Purevjav2012Molecular). Specific mutations, such as Y20C and Q529X, disrupt the protein's functional domains, affecting its interactions with other proteins like α-actinin and nebulette, which are crucial for sarcomere assembly and cardiac signaling (Purevjav2012Molecular).

MYPN mutations are also linked to nemaline myopathy (NM), a skeletal muscle disorder characterized by muscle weakness and the presence of nemaline bodies in muscle fibers. Biallelic mutations in MYPN can cause childhood-onset, slowly progressive NM, with symptoms such as mild muscle weakness and cardiac abnormalities (Miyatake2017Biallelic). The pathogenicity of MYPN mutations in cardiomyopathy and NM may vary based on mutation type, zygosity, and molecular mechanisms, with some mutations exhibiting dominant-negative effects (Miyatake2017Biallelic; Purevjav2012Molecular). These findings underscore the clinical significance of MYPN in both cardiac and skeletal muscle diseases.

## Interactions
Myopalladin (MYPN) is a sarcomeric protein that plays a crucial role in muscle structure and function through its interactions with various proteins. It binds to the SH3 domains of nebulin and nebulette, anchoring them within the Z-line of muscle cells. This interaction is mediated by a proline-rich stretch within the IS3 domain of myopalladin, with a critical proline residue triplet (PPP) at positions 649-651 (Bang2001Myopalladin). Myopalladin also interacts with α-actinin through its COOH-terminal region, which is essential for forming a structural link within the sarcomere (Bang2001Myopalladin).

In addition to its structural roles, myopalladin binds to the cardiac ankyrin repeat protein (CARP) in the NH2-terminal region, suggesting a role in muscle gene regulation (Bang2001Myopalladin). Myopalladin is involved in the serum response factor (SRF) pathway, interacting with myocardin-related transcription factors (MRTFs) to enhance SRF signaling, which is crucial for muscle growth and differentiation (Filomena2019Myopalladin). These interactions highlight myopalladin's multifaceted role in maintaining muscle integrity and function.


## References


[1. (Filomena2019Myopalladin) Maria Carmela Filomena, Daniel L. Yamamoto, Marco Caremani, Vinay K. Kadarla, Giuseppina Mastrototaro, Simone Serio, Anupama Vydyanath, Margherita Mutarelli, Arcamaria Garofalo, Irene Pertici, Ralph Knöll, Vincenzo Nigro, Pradeep K. Luther, Richard L. Lieber, Moriah R. Beck, Marco Linari, and Marie‐Louise Bang. Myopalladin promotes muscle growth through modulation of the serum response factor pathway. Journal of Cachexia, Sarcopenia and Muscle, 11(1):169–194, October 2019. URL: http://dx.doi.org/10.1002/jcsm.12486, doi:10.1002/jcsm.12486. This article has 26 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/jcsm.12486)

[2. (Filomena2021Myopalladin) Maria Carmela Filomena, Daniel L Yamamoto, Pierluigi Carullo, Roman Medvedev, Andrea Ghisleni, Nicoletta Piroddi, Beatrice Scellini, Roberta Crispino, Francesca D’Autilia, Jianlin Zhang, Arianna Felicetta, Simona Nemska, Simone Serio, Chiara Tesi, Daniele Catalucci, Wolfgang A Linke, Roman Polishchuk, Corrado Poggesi, Mathias Gautel, and Marie-Louise Bang. Myopalladin knockout mice develop cardiac dilation and show a maladaptive response to mechanical pressure overload. eLife, September 2021. URL: http://dx.doi.org/10.7554/elife.58313, doi:10.7554/elife.58313. This article has 14 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.7554/elife.58313)

[3. (Purevjav2012Molecular) Enkhsaikhan Purevjav, Takuro Arimura, Sibylle Augustin, Anne-Cecile Huby, Ken Takagi, Shinichi Nunoda, Debra L. Kearney, Michael D. Taylor, Fumio Terasaki, Johan M. Bos, Steve R. Ommen, Hiroki Shibata, Megumi Takahashi, Manatsu Itoh-Satoh, William J. McKenna, Ross T. Murphy, Siegfried Labeit, Yoichi Yamanaka, Noboru Machida, Jeong-Euy Park, Peta M.A. Alexander, Robert G. Weintraub, Yasushi Kitaura, Michael J. Ackerman, Akinori Kimura, and Jeffrey A. Towbin. Molecular basis for clinical heterogeneity in inherited cardiomyopathies due to myopalladin mutations. Human Molecular Genetics, 21(9):2039–2053, January 2012. URL: http://dx.doi.org/10.1093/hmg/dds022, doi:10.1093/hmg/dds022. This article has 84 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/dds022)

[4. (Miyatake2017Biallelic) Satoko Miyatake, Satomi Mitsuhashi, Yukiko K. Hayashi, Enkhsaikhan Purevjav, Atsuko Nishikawa, Eriko Koshimizu, Mikiya Suzuki, Kana Yatabe, Yuzo Tanaka, Katsuhisa Ogata, Satoshi Kuru, Masaaki Shiina, Yoshinori Tsurusaki, Mitsuko Nakashima, Takeshi Mizuguchi, Noriko Miyake, Hirotomo Saitsu, Kazuhiro Ogata, Mitsuru Kawai, Jeffrey Towbin, Ikuya Nonaka, Ichizo Nishino, and Naomichi Matsumoto. Biallelic mutations in mypn , encoding myopalladin, are associated with childhood-onset, slowly progressive nemaline myopathy. The American Journal of Human Genetics, 100(1):169–178, January 2017. URL: http://dx.doi.org/10.1016/j.ajhg.2016.11.017, doi:10.1016/j.ajhg.2016.11.017. This article has 65 citations.](https://doi.org/10.1016/j.ajhg.2016.11.017)

[5. (Caremani2014The) Marco Caremani, Daniel L. Yamamoto, Vincenzo Nigro, Vincenzo Lombardi, Marie Louise Bang, and Marco Linari. The role of myopalladin in skeletal muscle. Biophysical Journal, 106(2):767a, January 2014. URL: http://dx.doi.org/10.1016/j.bpj.2013.11.4215, doi:10.1016/j.bpj.2013.11.4215. This article has 1 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bpj.2013.11.4215)

[6. (Bang2001Myopalladin) Marie-Louise Bang, Ryan E. Mudry, Abigail S. McElhinny, Karoly Trombitás, Adam J. Geach, Rob Yamasaki, Hiroyuki Sorimachi, Henk Granzier, Carol C. Gregorio, and Siegfried Labeit. Myopalladin, a novel 145-kilodalton sarcomeric protein with multiple roles in z-disc and i-band protein assemblies. The Journal of Cell Biology, 153(2):413–428, April 2001. URL: http://dx.doi.org/10.1083/jcb.153.2.413, doi:10.1083/jcb.153.2.413. This article has 222 citations.](https://doi.org/10.1083/jcb.153.2.413)